. Author manuscript; available in PMC: 2017 Jun 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2016 Mar 8;22(6):1094–1101. doi: 10.1016/j.bbmt.2016.02.017

TABLE 5.

Prediction of subsequent risk of cardiomyopathy, area under the curve (95% CI).

Model components	Cardiomyopathy before 1 year		Cardiomyopathy after 1 year
Model components	All patients N=479	Genetic data only N=288	All patients N=525	Genetic data only N=313
Model 1: gender, anthracycline dose category, and pre-transplant chest radiation based on coefficients from early cardiomyopathy logistic regression model	0.68 (0.60–0.76)	0.71 (0.62–0.81)	0.60 (0.54–0.67)	0.57 (0.49–0.66)

Model 2: model 1 plus pretransplant hypertension and dyslipidemia	0.76 (0.68–0.83)^*	0.78 (0.69–0.87)^†	0.59 (0.53–0.67)	0.60 (0.51–0.68)

Model 3: model 2 plus all category 1–3 SNPs with OR’s ≥1.3	-	0.76 (0.65–0.86)	-	0.58 (0.49–0.67)

Model 4: gender, anthracycline dose category, total body irradiation, donor status, chronic GVHD, pre-transplant hypertension and diabetes, and post-transplant relapse based on coefficients from late cardiomyopathy proportional hazards model	-	-	0.61 (0.55–0.68)	0.62 (0.54–0.71)

Difference in model fit, compared with Model 1, p=0.02.

^†

Difference in model fit, compared with Model 1, p=0.09.